<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1880">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136690</url>
  </required_header>
  <id_info>
    <org_study_id>4334-007</org_study_id>
    <secondary_id>MK-4334-007</secondary_id>
    <nct_id>NCT05136690</nct_id>
  </id_info>
  <brief_title>Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Cross-over Evaluation of Evoked Responses as Pharmacodynamic Biomarkers in Healthy Adults and Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this randomized, double-blind, placebo-controlled cross-over study is&#xD;
      to record and measure 40 Hz-auditory steady-state response (ASSR) in healthy controls (HC)&#xD;
      and participants with mild-to-moderate schizophrenia (SZ) to determine if the mean&#xD;
      inter-trial coherence (ITC) magnitude derived from the 40 Hz-ASSR is lower in SZ than in HC&#xD;
      at baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-part study. Part 1 is a 2-period study in which participants receive 21 mg&#xD;
      nicotine patches or placebo patches, each with placebo capsules, in Period 1 and Period 2&#xD;
      under a cross-over design. In Part 2 (Period 3), participants are randomized to receive&#xD;
      either MK-4334 250 mg capsule or placebo capsule, each with placebo patches.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 5, 2022</start_date>
  <completion_date type="Anticipated">June 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean inter-trial coherence (ITC) magnitude of 40 Hz-derived auditory steady-state response (ASSR) in HC and SZ participants</measure>
    <time_frame>Day -1</time_frame>
    <description>The magnitude of ITC of 40 Hz-derived ASSR will be measured and recorded at baseline (Day -1) to determine if ITC differs between HC and SZ participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration deviant mismatch negativity (DD-MMN) in HC and SZ participants</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean MMN magnitude derived from baseline DD-MMN will be compared in HC and SZ participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of nicotine on mean ITC magnitude of 40 Hz-derived ASSR in HC and SZ participants</measure>
    <time_frame>Day 1 or Day 8</time_frame>
    <description>The effects of nicotine and placebo patches on 40 Hz-derived ASSR will be determined in HC and SZ participants on Day 1 or Day 8 in a counterbalanced order.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma nicotine level during event related potential (ERP) recording</measure>
    <time_frame>Day 1 or Day 8</time_frame>
    <description>Plasma nicotine levels will be determined during nicotine patch test sessions occurring on Day 1 or Day 8 in a counterbalanced order.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Cognitive Impairment Associated With Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Panel A: Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, HC participants receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), HC participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: Schizophrenic Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, SZ participants receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), SZ participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>Nicotine 21 mg transdermal nicotine patch.</description>
    <arm_group_label>Panel A: Healthy Controls</arm_group_label>
    <arm_group_label>Panel B: Schizophrenic Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-4334</intervention_name>
    <description>MK-4334 250 mg capsule taken by mouth.</description>
    <arm_group_label>Panel A: Healthy Controls</arm_group_label>
    <arm_group_label>Panel B: Schizophrenic Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>Placebo transdermal patch.</description>
    <arm_group_label>Panel A: Healthy Controls</arm_group_label>
    <arm_group_label>Panel B: Schizophrenic Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo capsule taken by mouth.</description>
    <arm_group_label>Panel A: Healthy Controls</arm_group_label>
    <arm_group_label>Panel B: Schizophrenic Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        HC Participants:&#xD;
&#xD;
          -  Is in generally good health&#xD;
&#xD;
          -  Has no history of clinically relevant neuropsychiatric illness&#xD;
&#xD;
          -  Is a mild-to-moderate tobacco user of ≥1-year duration, smoking the equivalent of&#xD;
             ~10-15 cigarettes/day&#xD;
&#xD;
        SZ Participants:&#xD;
&#xD;
          -  Has a current diagnosis of schizophrenia with a duration ≥1 year&#xD;
&#xD;
          -  Is clinically stable and in the residual (non-acute) phase of illness for ≥12 weeks&#xD;
             prior to the study&#xD;
&#xD;
          -  Is on a stable regimen of up to 2 first- or second-generation antipsychotic or other&#xD;
             concomitant medication commonly prescribed to this population&#xD;
&#xD;
          -  Is a mild-to-moderate tobacco user of ≥1-year duration, smoking the equivalent of&#xD;
             ~10-15 cigarettes/day&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  For males, agrees to be abstinent from heterosexual intercourse, or use an approved&#xD;
             contraception method, during the study and for 90 days after the last dose of study&#xD;
             drug&#xD;
&#xD;
          -  For females, is not of childbearing potential&#xD;
&#xD;
          -  Is willing to comply with restrictions on the use of nicotine or nicotine-containing&#xD;
             products during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        HC Participants:&#xD;
&#xD;
          -  Has known biological family history of psychotic disorder in a first or second degree&#xD;
             relative&#xD;
&#xD;
        SZ Participants:&#xD;
&#xD;
          -  May be excluded from participation by the investigator based on treatment history&#xD;
             and/or performance on various screening tests&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies, or human&#xD;
             immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Is at imminent risk of self-harm&#xD;
&#xD;
          -  Has had major surgery or donated blood within 4 weeks prior to screening&#xD;
&#xD;
          -  Has evidence of cognitive impairment or significant mental disability&#xD;
&#xD;
          -  Has a history of clinically significant abnormality or disease&#xD;
&#xD;
          -  Has a history of cancer (malignancy)&#xD;
&#xD;
          -  Is unable to refrain, or anticipates use, of any prohibited prescription or&#xD;
             non-prescription therapy&#xD;
&#xD;
          -  Has participated in another clinical study within 6 weeks or 5 half-lives (whichever&#xD;
             is greater) prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

